The firm’s stability program was inadequate in that the firm’s QC Laboratory failed to utilize a stability indicating method for assay testing of(b) (4) The QC Laboratory utilizes a titration method for assay testing of (b) (4) for all stability testing that the firm has conducted on their(B) (4) API products including the following US marketed API:(B) (4) For example, the firm utilized the titration assay method for the accelerated stability studies of(D) (4) API (lot#s(b) (4) The data from the accelerated stability studies was later utilized to determine the shelf life of the product.
Inspection Record
Titan Kogyo, Ltd — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
The firm's Production Unit utilizes critical raw materials within the manufacturing process prior to the completion of identification testing and release of the raw materials by the firm's Quality Control Unit.
Equipment and utensils utilized in the production of API for the US Market are not cleaned or maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, purity and quality of the drug substance.
Verification testing of the raw material supplier COA is inadequate as the firm has failed to conduct all of the analyses listed on the respective supplier COA.
A record as of the US FDA document published on 2026-11-05. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.